Neuroblastoma
"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 | | 1998 | 2 | 0 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 2 | 1 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 5 | 4 | 9 | | 2007 | 7 | 2 | 9 | | 2008 | 5 | 0 | 5 | | 2009 | 4 | 1 | 5 | | 2010 | 4 | 0 | 4 | | 2011 | 2 | 0 | 2 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 2 | 3 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 4 | 3 | 7 | | 2018 | 7 | 4 | 11 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 6 | 0 | 6 | | 2022 | 8 | 0 | 8 | | 2023 | 5 | 0 | 5 | | 2024 | 4 | 2 | 6 | | 2025 | 7 | 1 | 8 | | 2026 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Pinto N, Künkele A, Albert CM, Taylor MR, Ullom HB, Vitanza NA, Wilson AL, Cole BL, Yeung CCS, Wright JH, Huang W, Wendler J, Seidel K, Brown C, Gustafson J, Rawlings-Rhea SD, Beebe A, Mgebroff S, Gardner RA, Jensen MC, Park JR. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clin Cancer Res. 2026 Sep 15; 32(18):4062-4074.
-
Buenger V, Bauer J, Diamond J, Fader M, Hansen S, Kraveka JM, Schoen J, Shearer A, Sherwood D. Bridging the Gap in Neuroblastoma Care: Consensus-Based Statements With Recommendations for Improved Patient and Caregiver Experiences. Pediatr Blood Cancer. 2026 Sep; 73(9):e70551.
-
Sokol E, Naranjo A, Chen L, Mody R, DuBois SG, Bagatell R, Pinto N. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2026 Sep; 73(9):e70504.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Hazard FK, Toland AMS, Tan SY, Chiu B, Ikegaki N, Naranjo A, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Reshmi SC, Wagner E, Nuchtern J, Asgharzadeh S, Marachelian A, Maris JM, Bagatell R, Park JR, Irwin MS, Hogarty MD, Shimada H. Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134.
-
Hudda Z, Webster A, Anderson E, Badia P, Bagatell R, Bhar S, Bidgoli A, Boyd K, Chaudhury S, Cisneros GS, Craddock J, Davies SM, Desai AV, Drobatz L, Dvorak CC, Elkus H, Fabrizio VA, Foster JH, Fraint E, Freedman JL, Galvez J, Garcia M, Haight A, Higham C, Jodele S, Kamat A, Kaviany S, Lehmann L, Leung K, Lind KT, Llaurador G, Kapadia M, Khazal S, Massi K, Mormann M, Pater L, Rangarajan HG, Rotz S, Sabulski A, Sartain SE, Schoettler ML, Sokol E, Streby KA, Stein M, Verneris MR, Weiss BD, Yazdani S, Zheng D, Dandoy CE. Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study. Transplant Cell Ther. 2026 Feb; 32(2):199.e1-199.e12.
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
-
Taylor MR, Anderson JR, Park JR, Irwin MS, Applebaum MA, Pinto NR, Streby K, Federico SM, Rosswog C, Ohira M, Kao PC, London WB, Cash T. Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project. Pediatr Blood Cancer. 2025 11; 72(11):e31968.
-
Mansfield SA, Kotagal M, Hartman SJ, Murphy AJ, Hogan B, Ha D, Anghelescu DL, Mecoli M, Cost NG, Davidoff AM, Rove KO. Enhanced Recovery After Surgery (ERAS) Improves Length of Stay and Decreases Complications After Resection of Abdominal Neuroblastoma. Pediatr Blood Cancer. 2025 11; 72(11):e31971.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|